Opportunity Information: Apply for RFA NR 10 002
Apply for RFA NR 10 002
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.361 Nursing Research.
- This funding opportunity was created on Feb 4, 2010 and posted on Feb 4, 2010.
- Applicants must submit their applications by May 5, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,875,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments Independent school districts Public and State controlled institutions of higher education County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) City or township governments Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Public housing authorities/Indian housing authorities Small businesses For profit organizations other than small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity "Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R21)" (Funding Opportunity Number RFA-NR-10-002) is a National Institutes of Health program issued through the National Institute of Nursing Research (NINR). It is aimed at supporting exploratory, early-stage research projects that either dig into the underlying mechanisms behind chronic co-morbid health conditions seen in U.S. adults living with HIV who are receiving effective antiretroviral therapy (ART), or test interventions intended to prevent, reduce, or manage those conditions. The central idea is that as ART has improved and people with HIV are living longer, long-term chronic conditions are becoming a major part of the health picture, and there is still a need to better understand how these conditions develop over time and what can be done about them in real-world clinical and behavioral contexts.
The scientific focus is on chronic co-morbidities that may be driven by the HIV disease process itself, by long-term exposure to ART, or by the interaction of HIV, treatment, aging, and other risk factors. The announcement highlights examples such as cachexia (wasting), diabetes, kidney disease, neurological changes, cardiovascular disease, and cancer. While many of these conditions also affect older adults without HIV, the FOA emphasizes that HIV-positive adults may experience different patterns, timing, severity, or combinations of these illnesses. Because of that, NINR is seeking research that clarifies the natural history of these co-morbid conditions specifically in HIV-treated adults, including both biological manifestations (for example, physiological changes and biomarkers) and behavioral manifestations (for example, symptoms, functioning, adherence-related behaviors, lifestyle factors, and other patient-centered outcomes). A key motivation is that ART has evolved substantially since the introduction of protease inhibitors in the late 1990s, including the rise of customized combination regimens, and the NIH wants the field to reassess emerging risks and opportunities tied to modern treatment approaches as people with HIV move through middle and older age.
This FOA uses the NIH R21 mechanism, which is typically designed for exploratory or developmental work, such as proof-of-concept studies, early intervention testing, or mechanistic research that can generate strong preliminary data for later, larger trials or longer-term projects. The announcement notes that this R21 opportunity runs in parallel with an R01 companion FOA (RFA-NR-10-001) that covers the same scientific scope but supports more extensive research programs. In practice, that means applicants should align their project scale with the R21 intent: focused, innovative, and positioned to open up a new line of inquiry or demonstrate feasibility rather than deliver a fully powered definitive trial.
The program encourages interdisciplinary and multidisciplinary teams, reflecting how chronic co-morbidities in HIV often span clinical care, symptom science, aging, behavioral health, pharmacology, and social determinants of health. It also explicitly encourages teams that include investigators who are underrepresented minorities, individuals with disabilities, or women investigators, signaling an interest in broad participation and leadership diversity in the research community.
On the administrative side, the opportunity is a discretionary grant in the health and education/nursing research area (CFDA 93.361, Nursing Research) and does not require cost sharing or matching funds. The estimated total funding listed is $1,875,000, with an award ceiling of $200,000. The FOA was posted February 4, 2010, with an original and current closing date of May 5, 2010, and an archive date of June 5, 2010 (meaning it is no longer open, but it remains useful as a reference for the types of projects NINR has sought). Eligibility is broad and includes many types of U.S. organizations and governments, such as public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), small businesses, for-profit organizations (including those other than small businesses), state and local governments, tribal governments and tribal organizations, public housing authorities, independent school districts, and a range of special categories such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, faith-based and community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
Overall, this R21 announcement is essentially a call to sharpen the science around what chronic conditions look like in the modern ART era, why they arise, and how to intervene effectively, with special attention to the complex mix of biological and behavioral factors that shape long-term health for adults living with HIV in the United States.
Frequently Asked Questions (FAQs)
What is the official title of this grant opportunity?
The opportunity is titled "Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R21)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-NR-10-002.
Which federal agency and institute issued this FOA?
This is a National Institutes of Health (NIH) program issued through the National Institute of Nursing Research (NINR).
What type of grant mechanism does this FOA use?
This FOA uses the NIH R21 mechanism, which is intended for exploratory or developmental research projects.
What kinds of projects is this FOA trying to support?
It supports exploratory, early-stage research projects that either (1) investigate underlying mechanisms behind chronic co-morbid health conditions in U.S. adults living with HIV who are receiving effective antiretroviral therapy (ART), or (2) test interventions intended to prevent, reduce, or manage those chronic co-morbid conditions.
Why is NIH/NINR focused on chronic co-morbidities in people with HIV who are on effective ART?
The FOA is based on the idea that improvements in ART have allowed people with HIV to live longer, and as a result, long-term chronic conditions have become a major part of their health picture. NINR is seeking research to better understand how these conditions develop over time and what can be done about them in clinical and behavioral contexts.
What populations are the focus of this announcement?
The focus is on U.S. adults living with HIV who are receiving highly effective antiretroviral therapy (ART), including people moving through middle and older age.
What is meant by "chronic co-morbid conditions" in this FOA?
In this context, chronic co-morbid conditions are long-term health conditions that occur alongside HIV in adults on ART. The FOA emphasizes that these conditions may be driven by the HIV disease process, long-term ART exposure, or the interaction of HIV, treatment, aging, and other risk factors.
What examples of chronic co-morbidities are mentioned?
The FOA highlights examples such as cachexia (wasting), diabetes, kidney disease, neurological changes, cardiovascular disease, and cancer.
Does the FOA suggest that co-morbidities may look different in HIV-treated adults compared to adults without HIV?
Yes. The FOA notes that while many chronic conditions also affect older adults without HIV, adults living with HIV may experience different patterns, timing, severity, or combinations of these illnesses.
What kinds of research questions fit the "mechanisms" side of this FOA?
Mechanistic projects can focus on clarifying how chronic co-morbid conditions arise in HIV-treated adults, including biological processes associated with HIV, ART, aging, and other interacting risks. The FOA also points to studying physiological changes and biomarkers as examples of biological manifestations.
What kinds of research questions fit the "intervention" side of this FOA?
Intervention projects can test approaches intended to prevent, reduce, or manage chronic co-morbid conditions in this population, with attention to real-world clinical and behavioral contexts.
What outcomes or domains does NINR emphasize beyond biology?
The FOA emphasizes both biological and behavioral manifestations. Behavioral examples include symptoms, functioning, adherence-related behaviors, lifestyle factors, and other patient-centered outcomes.
Why does the FOA mention changes in ART over time?
The FOA points out that ART has evolved substantially since the late 1990s, including customized combination regimens. It calls for reassessing emerging risks and opportunities tied to modern treatment approaches as people with HIV age.
How should applicants think about the project scope under an R21?
Applicants are expected to align with the R21 intent: focused, innovative, and designed to open a new line of inquiry, demonstrate feasibility, provide proof-of-concept, conduct early intervention testing, or generate preliminary data for later, larger studies, rather than deliver a fully powered definitive trial.
Is there a related FOA for larger projects?
Yes. This R21 opportunity runs in parallel with a companion R01 FOA, RFA-NR-10-001, which covers the same scientific scope but supports more extensive research programs.
Does the program encourage particular team structures or disciplines?
Yes. The FOA encourages interdisciplinary and multidisciplinary teams, reflecting that chronic co-morbidities in HIV can span clinical care, symptom science, aging, behavioral health, pharmacology, and social determinants of health.
Does the FOA encourage participation by specific investigator groups?
Yes. It explicitly encourages teams that include investigators who are underrepresented minorities, individuals with disabilities, or women investigators, reflecting interest in broad participation and leadership diversity.
What is the CFDA number and program area listed for this opportunity?
The CFDA is 93.361, Nursing Research, and it is described as a discretionary grant in the health and education/nursing research area.
Is cost sharing or matching required?
No. The FOA states that it does not require cost sharing or matching funds.
How much total funding was estimated for the program?
The FOA lists an estimated total funding amount of $1,875,000.
What is the award ceiling mentioned in the FOA?
The award ceiling listed is $200,000.
When was the FOA posted, and what were the key dates?
The FOA was posted on February 4, 2010. The original and current closing date was May 5, 2010. The archive date was June 5, 2010.
Is this FOA currently open to applications?
No. The archive date (June 5, 2010) indicates it is no longer open, though it may still be useful as a reference for the types of projects NINR has sought.
What types of organizations are eligible to apply?
Eligibility is broad and includes many types of U.S. organizations and governments, including public and private institutions of higher education; nonprofits (including 501(c)(3) and certain non-501(c)(3) entities); small businesses; for-profit organizations (including those other than small businesses); state and local governments; tribal governments and tribal organizations; public housing authorities; independent school districts; eligible federal agencies; regional organizations; U.S. territories or possessions; and additional categories such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and faith-based and community-based organizations.
Does the FOA limit eligibility only to nursing schools or nursing departments?
The FOA is issued by NINR and is listed under Nursing Research (CFDA 93.361), but the eligibility list includes a wide range of organization types and does not state that applicants must be nursing schools or nursing departments.
What is the main scientific theme or "central idea" of the FOA?
The central theme is improving understanding of what chronic conditions look like in the modern ART era, why they arise, and how to intervene effectively, with attention to the mix of biological and behavioral factors shaping long-term health for U.S. adults living with HIV.
Browse more opportunities from the same category: Education Health
Next opportunity: Great Divide Sand Tailings Removal in Montana
Previous opportunity: NIJ FY 2010 Alternatives to Conduct Energy Less Lethal Devices
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA NR 10 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA NR 10 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) Apply for PA 10 108 Funding Number: PA 10 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Comprehensive Partnerships to Reduce Cancer Health Disparities (Limited Competition U54) Apply for RFA CA 10 503 Funding Number: RFA CA 10 503 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R21) Apply for RFA NR 10 007 Funding Number: RFA NR 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R01) Apply for RFA NR 10 006 Funding Number: RFA NR 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Common Pathogenetic Mechanisms of Lung Cancer and COPD (R01) Apply for RFA HL 11 002 Funding Number: RFA HL 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Clinical Trials in Drug Abuse (Collaborative R01) Apply for PAR 10 099 Funding Number: PAR 10 099 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Strategic Partnering to Evaluate Cancer Signatures SPECS II (U01) Apply for PAR 10 126 Funding Number: PAR 10 126 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (Competitive Revision R01) Apply for RFA NR 10 005 Funding Number: RFA NR 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (R01) Apply for RFA NR 10 004 Funding Number: RFA NR 10 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R03) Apply for PA 10 131 Funding Number: PA 10 131 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R01) Apply for PA 10 129 Funding Number: PA 10 129 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R21) Apply for PA 10 130 Funding Number: PA 10 130 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Medical Education Partnership Initiative (MEPI) (R24) Apply for RFA TW 10 008 Funding Number: RFA TW 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Research Education Program for Laboratory Animal Medicine Veterinarians (R25) Apply for RFA RR 10 002 Funding Number: RFA RR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $224,000 |
| Next Generation Genetic Association Studies (U01) Apply for RFA HL 11 006 Funding Number: RFA HL 11 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Cancer Prevention Studies Involving Molecular Targets for Bioactive Food Components (R21) Apply for PA 10 088 Funding Number: PA 10 088 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Development of Animal Models and Related Biological Materials For Research (R21) Apply for PA 10 138 Funding Number: PA 10 138 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Diet Composition and Energy Balance (R01) Apply for PA 10 152 Funding Number: PA 10 152 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Paul Calabresi Career Development Award for Clinical Oncology (K12) Apply for PAR 10 155 Funding Number: PAR 10 155 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Identification and Characterization of Molecular Targets Within the mTOR Pathway With Potential to Impact Healthspan and Lifespan (R21) Apply for PA 10 164 Funding Number: PA 10 164 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA NR 10 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.